Multiple positivity in tests investigating the presence of antiphospholipid antibodies (aPL) [criteria aPL comprehend: lupus anti-coagulant (LA), anticardiolipin (aCL), and anti-β2–glycoprotein I (aβ2GPI) antibodies] are now widely recognized as being associated with a higher risk of developing thromboembolic events (TEs). The gene discussed is ACLY; the disease is systemic lupus erythematosus.